Lip and Oral Cavity Carcinoma

Diseases /

Lip and Oral Cavity Carcinoma

Back to Diseases List

Associated Genetic Biomarkers

ABL1
ABL1 Amplification
ABL1 Fusion
ABL1 Mutation
BRAF
BRAF Amplification
BRAF Mutation
CDKN2A Overexpression
DDR2
DDR2 Amplification
DDR2 Mutation
EGFR
EGFR Amplification
EGFR Mutation
EPHA2
EPHA2 Amplification
EPHA2 Mutation
ERBB2
ERBB2 Amplification
ERBB2 Mutation

ERBB4
ERBB4 Amplification
ERBB4 Loss
ERBB4 Mutation
FGFR1
FGFR1 Amplification
FGFR1 Fusion
FGFR1 Mutation
FGFR2
FGFR2 Amplification

FGFR2 Fusion
FGFR2 Mutation
FLT1
FLT1 Amplification
FLT1 Mutation
FLT4
FLT4 Amplification
FLT4 Mutation
FRK
FRK Mutation

HPV Negative
KDR
KDR Amplification
KDR Mutation
KIT
KIT Amplification
KIT Fusion
KIT Mutation
MAPK11
MAPK11 Amplification

MAPK11 Mutation
PDGFRA
PDGFRA Amplification
PDGFRA Fusion
PDGFRA Mutation
PDGFRB
PDGFRB Amplification
PDGFRB Fusion
PDGFRB Mutation
RAF1

RAF1 Amplification
RAF1 Mutation
RET
RET Amplification
RET Fusion
RET Mutation
TEK
TEK Mutation
TRNAK2
TRNAK2 Mutation

VEGFA
VEGFA Amplification
VEGFB
VEGFB Amplification
VEGFC
VEGFC Amplification
del(11)(p10)
del(13)(q10)
del(17)(p10)
del(3)(p14)

del(4)(q10)
del(8)(p10)
del(9)(p21)

Overview

NCI Definition: A carcinoma arising in the lip or oral cavity. Most oral cavity carcinomas are squamous cell carcinomas of the tongue, buccal mucosa, or gums. Less frequent morphologic variants include mucoepidermoid carcinoma and adenocarcinoma. Lip carcinomas are usually basal cell or squamous cell carcinomas. [1]

Clinical Trials

View Clinical Trials for Lip and Oral Cavity Carcinoma

There are 5 clinical trials for lip and oral cavity carcinoma, of which 3 are open and 2 are completed or closed. Of the trials that contain lip and oral cavity carcinoma as an inclusion criterion, 1 is early phase 1 (0 open), 3 are phase 2 (3 open), and 1 is no phase specified (0 open).

ABL1, BRAF, and DDR2 are the most frequent gene inclusion criteria for lip and oral cavity carcinoma clinical trials [3].

Trials Investigating Lip And Oral Cavity Carcinoma by Gene and Recruiting Status

Pembrolizumab, afatinib, and cabozantinib are the most common interventions in lip and oral cavity carcinoma clinical trials.

Drugs Being Investigated in Lip And Oral Cavity Carcinoma Trials by Recruiting Status

Significant Genes in Lip and Oral Cavity Carcinoma

ABL1 +

ABL1 is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF +

BRAF is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

DDR2 +

DDR2 is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DDR2 status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR +

EGFR is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EPHA2 +

EPHA2 is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 +

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB4 +

ERBB4 is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB4 status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR1 +

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR2 +

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT1 +

FLT1 is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT4 +

FLT4 is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FRK +

FRK is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FRK status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KDR +

KDR is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT +

KIT is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MAPK11 +

MAPK11 is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK11 status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA +

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRB +

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAF1 +

RAF1 is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RET +

RET is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TEK +

TEK is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TEK status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TRNAK2 +

TRNAK2 is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TRNAK2 status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFA +

VEGFA is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFA status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFB +

VEGFB is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFC +

VEGFC is an inclusion eligibility criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFC status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Disease Details

Synonyms

Oral Cancer, Oral Carcinoma, Lip and Oral Cavity Cancer

Parent(s)

Malignant Oral Neoplasm

Children

Lip Carcinoma and Oral Cavity Carcinoma

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Lip and Oral Cavity Carcinoma

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Lip and Oral Cavity Carcinoma

Disease Details

References

About

Molecular Medicine

Content Types